Published in Facts Views Vis Obgyn on January 01, 2015
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol (2013) 2.79
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol (2012) 2.48
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol (2014) 0.97
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. Ann Oncol (2001) 0.87
Clinical pharmacology of trastuzumab. Curr Clin Pharmacol (2008) 0.85
Subcutaneous administration of anticancer agents. Anticancer Res (2014) 0.83
Lean oncology: a new model for oncologists. J Transl Med (2012) 0.79